GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.

已取消 10 由不知道发布于 2024/7/15 21:04:10

DOI:10.1016/S2352-3026(22)00372-6
作者：Mingming Zhang, Guoqing Wei, Linghui Zhou, Jincai Zhou, Siye Chen, Wei Zhang, Dongrui Wang, Xueping Luo, Jiazhen Cui, Simao Huang, Shan Fu, Xinkai Zhou, Yu Tang, Xiaomin Ding, Jiao Kuang, Xiaowen Peter He, Yongxian Hu, He Huang
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) has shown activity in treating relapsed or refractory multiple myeloma; however, relapse

应助信息

2024-07-15

Book学术机器人

2024/7/15 21:04:10 未找到该文献，机器人已退出，请等待人工下载

2024/7/15 21:04:10 Book学术AI机器人收到请求，开始寻找文献

2024/7/15 21:04:10 已向机器人发送请求

2024-07-15

不知道发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)Highly Ion-Permselective Porous Organic Cage Membranes with Hierarchical Channels